{"filing":{"accession_number":"0001213900-26-092807","cik":"0001584371","ticker":"ICCM","company_name":"IceCure Medical Ltd.","form":"6-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"ea0303119-6k_icecure.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1584371/000121390026092807/ea0303119-6k_icecure.htm"},"events":[{"id":29072,"run_id":26601,"accession_number":"0001213900-26-092807","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"IceCure announced entry into an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands. This is a material operational/commercial event—a strategic partnership expanding the company's European commercialization footprint in a key market where the THERMAC clinical trial is advancing to Phase III. While not a discrete M\u0026A transaction, the exclusive distribution agreement represents a significant commercial milestone that would affect investor assessment of the company's market access and revenue potential.","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-08-24","form":"6-K","submitted_at":null,"items":[{"id":31227,"accession_number":"0001213900-26-092807","item_number":"EX-99.1","item_title":"ea030311901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"IceCure announced entry into an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands. This is a material operational/commercial event—a strategic partnership expanding the company's European commercialization footprint in a key market where the THERMAC clinical trial is advancing to Phase III. While not a discrete M\u0026A transaction, the exclusive distribution agreement represents a significant commercial milestone that would affect investor assessment of the company's market access and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:15:46.608739+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31227,"accession_number":"0001213900-26-092807","item_number":"EX-99.1","item_title":"ea030311901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"IceCure announced entry into an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands. This is a material operational/commercial event—a strategic partnership expanding the company's European commercialization footprint in a key market where the THERMAC clinical trial is advancing to Phase III. While not a discrete M\u0026A transaction, the exclusive distribution agreement represents a significant commercial milestone that would affect investor assessment of the company's market access and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-24T12:15:46.608739+00:00","company_name":"IceCure Medical Ltd.","ticker":"ICCM","filing_date":"2026-08-24"}]}